Extrait

To assess if a switch from MMF to myfortic® results in improved GI- and/or health-related quality of life outcomes, and to determine the proportion of patients with who are experiencing any GI complaints under MMF-based immunosuppressive treatment.

Critère d'inclusion

• patients with autoimmune diseases treated with MPA

Liens

• euctr
• ictrp